4.3 Article

Role of MYC in Medulloblastoma

期刊

出版社

COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/cshperspect.a014308

关键词

-

资金

  1. National Institutes of Health [CA-096832, CA-21765]
  2. American Lebanese-Syrian Associated Charities (AL-SAC) of St. Jude Children's Research Hospital (SJCRH)

向作者/读者索取更多资源

Since its discovery as an oncogene carried by the avian acute leukemia virus MC29 in myelocytomatosis (Roussel et al. 1979) and its cloning (Vennstrom et al. 1982), c-MYC (MYC), as well as its paralogs MYCN and MYCL1, has been shown to play essential roles in cycling progenitor cells born from proliferating zones during embryonic development, and in all proliferating cells after birth. MYC deletion induces cell-cycle exit or cell death, depending on the cell type and milieu, whereas MYC and MYCN amplification or overexpression promotes cell proliferation and occurs in many cancers. Here, we review the relationship of MYC family proteins to the four molecularly distinct medulloblastoma subgroups, discuss the possible roles MYC plays in each of these subgroups and in the developing cells of the posterior fossa, and speculate on possible therapeutic strategies targeting MYC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Medicine, Research & Experimental

Circulating tumor DNA profiling for childhood brain tumors: Technical challenges and evidence for utility

Anthony Pak-Yin Liu, Paul A. Northcott, Giles W. Robinson, Amar Gajjar

Summary: The use of cell-free DNA (cfDNA) profiling as a liquid biopsy has shown clinical value in adult-onset malignancies, but its application in childhood cancers, including brain tumors, requires further research. This review discusses the current status of using cfDNA analysis for pediatric central nervous system neoplasms, covering technical challenges, evidence for utility, and potential future developments.

LABORATORY INVESTIGATION (2022)

Article Oncology

Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study

John T. Lucas, Christopher L. Tinkle, Jie Huang, Arzu Onar-Thomas, Sudharsan Srinivasan, Parker Tumlin, Jared B. Becksfort, Paul Klimo, Frederick A. Boop, Giles W. Robinson, Brent A. Orr, Julie H. Harreld, Matthew J. Krasin, Paul A. Northcott, David W. Ellison, Amar Gajjar, Thomas E. Merchant

Summary: This study characterizes the patterns of progression in medulloblastoma and reveals distinct anatomical failure patterns across molecular subgroups. This suggests that subgroup-specific treatment strategies should be considered.

NEURO-ONCOLOGY (2022)

Article Oncology

The posterior fossa syndrome questionnaire: using science to inform practice

Molly E. Wickenhauser, Raja B. Khan, Darcy Raches, Jason M. Ashford, Kathryn M. W. Russell, Kristin Lyons, Giles W. Robinson, Amar Gajjar, Paul Klimo, Heather M. Conklin

Summary: This study describes the psychometric properties of a new questionnaire called the Posterior Fossa Syndrome Questionnaire (PFSQ), which aims to improve diagnostic consistency for posterior fossa syndrome (PFS) across clinical and research groups. The study found that different items of the PFSQ had varying sensitivity and specificity, and identified four main factors. The results of this study are important for accelerating the understanding of PFS etiology, predicting long-term impairments, and developing targeted interventions.

JOURNAL OF NEURO-ONCOLOGY (2022)

Article Oncology

Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor

Santhosh A. Upadhyaya, Olivia Campagne, Catherine A. Billups, Brent A. Orr, Arzu Onar-Thomas, Ruth G. Tatevossian, Roya Mostafavi, Jason R. Myers, Anna Vinitsky, Daniel C. Moreira, Holly B. Lindsay, Lindsay Kilburn, Patricia Baxter, Amy Smith, John R. Crawford, Sonia Partap, Anne E. Bendel, Dolly G. Aguilera, Kim E. Nichols, Evadnie Rampersaud, David W. Ellison, Paul Klimo, Zoltan Patay, Giles W. Robinson, Alberto Broniscer, Clinton F. Stewart, Cynthia Wetmore, Amar Gajjar

Summary: This study examines the use of Aurora kinase A inhibitor alisertib in children with recurrent AT/RT. The results show that alisertib is well tolerated in children with recurrent AT/RT, and approximately one-third of the patients observed stable disease or partial response.

NEURO-ONCOLOGY (2023)

Article Oncology

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

Ami Desai, Giles W. Robinson, Karen Gauvain, Ellen M. Basu, Margaret E. Macy, Luke Maese, Nicholas S. Whipple, Amit J. Sabnis, Jennifer H. Foster, Suzanne Shusterman, Janet Yoon, Brian D. Weiss, Mohamed S. Abdelbaki, Amy E. Armstrong, Thomas Cash, Christine A. Pratilas, Nadege Corradini, Lynley Marshall, Mufiza Farid-Kapadia, Saibah Chohan, Clare Devlin, Georgina Meneses-Lorente, Alison Cardenas, Katherine E. Hutchinson, Guillaume Bergthold, Hubert Caron, Edna Chow Maneval, Amar Gajjar, Elizabeth Fox

Summary: The study demonstrates that Entrectinib has rapid and durable responses in pediatric patients with solid tumors harboring NTRK1/2/3 or ROS1 fusions. In the phase 1 trial, four patients experienced dose-limiting toxicities, with weight gain and bone fractures being the most common treatment-related adverse events.

NEURO-ONCOLOGY (2022)

Article Oncology

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma

Allison Pribnow, Barbara Jonchere, Jingjing Liu, Kyle S. Smith, Olivia Campagne, Ke Xu, Sarah Robinson, Yogesh Patel, Arzu Onar-Thomas, Gang Wu, Clinton F. Stewart, Paul A. Northcott, Jiyang Yu, Giles W. Robinson, Martine F. Roussel

Summary: Combining ribociclib and gemcitabine can effectively slow down tumor progression and metastasis, and improve survival in patients with G3MB. Molecular analysis reveals significant changes in gene activity and expression, which may be related to cell cycle progression, DNA damage response, and neuronal differentiation. This study suggests that the combination therapy of ribociclib and gemcitabine is a promising treatment strategy for children with G3MB and deserves further investigation.

MOLECULAR CANCER THERAPEUTICS (2022)

Article Oncology

Fastigial nuclei surgical damage and focal midbrain disruption implicate PAG survival circuits in cerebellar mutism syndrome

Samuel S. McAfee, Silu Zhang, Ping Zou, Heather M. Conklin, Darcy Raches, Giles Robinson, Amar Gajjar, Raja Khan, Paul Klimo, Zoltan Patay, Matthew A. Scoggins

Summary: This study aims to explore the anatomical and neuronal basis of pediatric postoperative cerebellar mutism syndrome (CMS) following medulloblastoma resection. By analyzing patterns of surgical damage and secondary axonal degeneration, the study found that damage to the fastigial nuclei and their associated cerebellar cortices is strongly associated with CMS. Additionally, neuronal dysfunction in the ventral periaqueductal gray area and the left red nucleus were consistent findings in CMS cases.

NEURO-ONCOLOGY (2023)

Article Oncology

Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

Barbara Jonchere, Justin Williams, Frederique Zindy, Jingjing Liu, Sarah Robinson, Dana M. Farmer, Jaeki Min, Lei Yang, Jennifer L. Stripay, Yingzhe Wang, Burgess B. Freeman, Jiyang Yu, Anang A. Shelat, Zoran Rankovic, Martine F. Roussel

Summary: Despite improvement in medulloblastoma treatment, many patients with MYC and MYCN-driven tumors still do not benefit. High-throughput drug combination screens revealed that the combination of CDK4/6 inhibitors with BET or PI3K/mTOR inhibitors enhanced the inhibition of cell proliferation. However, this combination did not significantly improve the survival of G3 and SHH medulloblastoma-bearing mice in vivo.

MOLECULAR CANCER THERAPEUTICS (2023)

Article Chemistry, Medicinal

From PROTAC to inhibitor: Structure-guided discovery of potent and orally bioavailable BET inhibitors

Mladen Koravovic, Anand Mayasundari, Gordana Tasic, Fatemeh Keramatnia, Timothy R. Stachowski, Huarui Cui, Sergio C. Chai, Barbara Jonchere, Lei Yang, Yong Li, Xiang Fu, Ryan Hiltenbrand, Leena Paul, Vibhor Mishra, Jeffery M. Klco, Martine F. Roussel, William CK. Pomerantz, Marcus Fischer, Zoran Rankovic, Vladimir Savic

Summary: An X-ray structure of a CLICK chemistry-based BET PROTAC bound to BRD2(BD2) inspired the synthesis of JQ1 derived heterocyclic amides. These compounds displayed improved profiles compared to JQ1 and birabresib as potent BET inhibitors. A specific compound 1q (SJ1461) showed excellent affinity to both BRD4 and BRD2 and high potency in acute leukaemia and medulloblastoma cell lines. The co-crystal structure of 1q with BRD4-BD1 revealed polar interactions, explaining the observed affinity improvements. Furthermore, pharmacokinetic studies suggested that the heterocyclic amide moiety improved drug-like features. Our study led to the discovery of the potent and orally bioavailable BET inhibitor 1q (SJ1461) as a promising candidate for further development.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Editorial Material Oncology

Targeting protein folding in N-Myc-driven medulloblastoma

Gintvile Valinciute, Martine F. Roussel

Summary: Selective targeting of N-Myc-driven Sonic hedgehog (SHH) medulloblastoma has been a long-standing challenge, with limited targeted therapy opportunities. A recent study by Kuzuoglu-Ozturk et al. characterized the translatome of N-Myc-driven medulloblastoma and identified potential therapeutic targets. The study demonstrated that the protein folding machinery controlled by N-Myc could be pharmacologically inhibited, and validated the necessity of certain Hsp70 functions for medulloblastoma progression in vitro and in vivo.

MOLECULAR ONCOLOGY (2023)

Meeting Abstract Oncology

ENTRECTINIB IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH EXTRACRANIAL SOLID OR PRIMARY CNS TUMOURS HARBOURING NTRK1/2/3, ROS1, OR ALK FUSIONS: UPDATED DATA FROM STARTRK-NG

Ami Desai, Giles Robinson, Ellen Basu, Jennifer Foster, Amit Sabnis, Luke Maese, Janet Yoon, Thomas Cash, Christine Pratilas, Yeming Wu, Daniel Morgenstern, Cornelis Van Tilburg, Michela Casanova, Quentin Campbell-Hewson, Arnauld Verschuur, Lynley Marshall, Dennis T. L. Ku, Nadege Corradini, Huanmin Wang, Saibah Chohan, Alison Cardenas, Katherine Hutchinson, Clare Devlin, Jade Wulff, Amar Gajjar, Elisabeth Fox

PEDIATRIC BLOOD & CANCER (2022)

Meeting Abstract Oncology

RELAPSE SHH MEDULLOBLASTOMA (MB) IN YOUNG CHILDREN. ARE THERE ALTERNATIVES TO FULL-DOSE CRANIOSPINAL IRRADIATION?

Craig Erker, Brandon Craig, Simon Bailey, Maura Massimino, Valerie Larouche, Jonathan Finlay, Cassie Kline, George Michaiel, Ashley Margol, Kenneth Cohen, Chantel Cacciotti, Virginia Harrods, Kathleen Dorris, Mohammed Abdelbaki, Nisreen Amayiri, Zhihong Wang, Jordan Hansford, Juliette Hukin, Ralph Salloum, Lindsay Hoffmann, Jeffrey Murray, Kevin Ginn, Michal Zapotocky, Lorena Baroni, Stephen Gilheens, Dolly Aguiera, Claire Mazewski, Shafqat Shah, Douglas Strother, Amar Gajjar, Sabine Mueller, Paul Northcott, Steve Clifford, Giles Robinson, Eric Bouffet, Lucie Lafay-Cousin

PEDIATRIC BLOOD & CANCER (2022)

Meeting Abstract Oncology

SERIAL ASSESSMENT OF MEASURABLE RESIDUAL DISEASE IN MEDULLOBLASTOMA LIQUID BIOPSIES

Paul Northcott, Kyle Smith, Rahul Kumar, Leena Paul, Laure Bihannic, Tong Lin, Kendra Maass, Kristian Pajtler, Murali Chintagumpala, Jack Su, Eric Bouffet, Michael Fisher, Sridharan Gururangan, Richard Cohn, Tim Hassall, Jordan Hansford, Paul Klimo, Frederick Boop, Clinton Stewart, Julie Harreld, Thomas Merchant, Ruth Tatevossian, Geoffrey Neale, Matthew Lear, Jeffery Klco, Brent Orr, David Ellison, Richard Gilbertson, Arzu Onar-Thomas, Amar Gajjar, Giles Robinson

NEURO-ONCOLOGY (2022)

Meeting Abstract Oncology

CLINICAL AND MOLECULAR META-ANALYSIS OF THREE MAJOR MEDULLOBLASTOMA CLINICAL TRIALS (ACNS0331, SJMB03, ACNS0332) UNCOVERS NOVEL STRATEGIES TO IMPROVE RISK-STRATIFIED THERAPY

Kyle S. Smith, Catherine A. Billups, Sandeep K. Dhanda, Laure Bihannic, Aksana Vasilyeva, Yimei Li, Jeff M. Michalski, James M. Olsen, Sarah Leary, Maryam Fouladi, Amar Gajjar, Arzu Onar, Paul A. Northcott, Giles W. Robinson

NEURO-ONCOLOGY (2022)

Meeting Abstract Oncology

SJ901: PHASE I/II EVALUATION OF SINGLE AGENT MIRDAMETINIB (PD-0325901), A BRAIN-PENETRANT MEK1/2 INHIBITOR, FOR THE TREATMENT OF CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH LOW-GRADE GLIOMA (LGG)

Anna Vinitsky, Jason Chiang, Asim K. Bag, Olivia Campagne, Clinton F. Stewart, Paige Dunphy, Barry Shulkin, Qian Li, Tong Lin, Mary Ellen Hoehn, Jason N. Johnson, Jeffrey A. Towbin, Raja Khan, Ruth G. Tatevossian, Gregory T. Armstrong, Brian Potter, Heather Conklin, Todd Shearer, Susan Scott, Giles W. Robinson

NEURO-ONCOLOGY (2022)

暂无数据